tetano
Editor, Senior Moderator
J Med Virol
. 2023 Aug;95(8):e29007.
doi: 10.1002/jmv.29007. Azvudine therapy of common COVID-19 in hemodialysis patients
Shunlai Shang[SUP] 1 2 [/SUP], Bo Fu[SUP] 2 [/SUP], Yanqiu Geng[SUP] 3 [/SUP], Jian Zhang[SUP] 4 [/SUP], Dawei Zhang[SUP] 5 [/SUP], Fenglin Xiao[SUP] 6 [/SUP], Zhaojun Sheng[SUP] 7 [/SUP], Jingbo Zhai[SUP] 8 [/SUP], Wenge Li[SUP] 1 [/SUP], Xiangmei Chen[SUP] 2 [/SUP], Chunfu Zheng[SUP] 9 [/SUP], Qinggang Li[SUP] 2 [/SUP]
Affiliations
There is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID-19), especially on the application of 2'-deoxy-2'-β -fluoro-4'-azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients. After matching for age, sex, and other factors, 182 patients in the basic treatment group and 182 in the FNC group were included. The negative nucleic acid conversion rate of the FNC group was significantly higher than that of the basic treatment group, and viral loads, interleukin-6, and C-reactive protein were significantly lower than those of the basic treatment group (p < 0.05). There were no significant differences in liver function, renal function, or the number of adverse events between the two groups (p > 0.05). In conclusion, our study has provided novel evidence suggesting that the FNC scheme may be safe and effective compared to the basic treatment of hemodialysis patients with common COVID-19.
Keywords: Azvudine; COVID-19; SARS-CoV-2; adverse events; efficacy; hemodialysis.
. 2023 Aug;95(8):e29007.
doi: 10.1002/jmv.29007. Azvudine therapy of common COVID-19 in hemodialysis patients
Shunlai Shang[SUP] 1 2 [/SUP], Bo Fu[SUP] 2 [/SUP], Yanqiu Geng[SUP] 3 [/SUP], Jian Zhang[SUP] 4 [/SUP], Dawei Zhang[SUP] 5 [/SUP], Fenglin Xiao[SUP] 6 [/SUP], Zhaojun Sheng[SUP] 7 [/SUP], Jingbo Zhai[SUP] 8 [/SUP], Wenge Li[SUP] 1 [/SUP], Xiangmei Chen[SUP] 2 [/SUP], Chunfu Zheng[SUP] 9 [/SUP], Qinggang Li[SUP] 2 [/SUP]
Affiliations
- PMID: 37522276
- DOI: 10.1002/jmv.29007
There is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID-19), especially on the application of 2'-deoxy-2'-β -fluoro-4'-azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients. After matching for age, sex, and other factors, 182 patients in the basic treatment group and 182 in the FNC group were included. The negative nucleic acid conversion rate of the FNC group was significantly higher than that of the basic treatment group, and viral loads, interleukin-6, and C-reactive protein were significantly lower than those of the basic treatment group (p < 0.05). There were no significant differences in liver function, renal function, or the number of adverse events between the two groups (p > 0.05). In conclusion, our study has provided novel evidence suggesting that the FNC scheme may be safe and effective compared to the basic treatment of hemodialysis patients with common COVID-19.
Keywords: Azvudine; COVID-19; SARS-CoV-2; adverse events; efficacy; hemodialysis.